《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》解读

2023-01-15 天津医科大学肿瘤医院血液科 河北医科大学学报 发表于上海

本文对《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》主要更新内容进行解读,旨在提高对该少见疾病的认识和诊疗水平。 

中文标题:

《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》解读

发布日期:

2023-01-15

简要介绍:

套细胞淋巴瘤(mantle cell lymphoma, MCL)是一种异质性很强的非霍奇金淋巴瘤,具有独特生物学、病理和临床特征,大多数患者诊断时即为晚期,预后较差。近年来随着大剂量化疗、自体造血干细胞移植及新药研究的进展,患者生存期得到明显延长。本文对《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》主要更新内容进行解读,旨在提高对该少见疾病的认识和诊疗水平。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=7bf1f1c002929810, title=《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》解读, enTitle=, guiderFrom=河北医科大学学报 , authorId=0, author=, summary=本文对《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》主要更新内容进行解读,旨在提高对该少见疾病的认识和诊疗水平。 , cover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PAJM2K5.jpg, journalId=0, articlesId=null, associationId=3960, associationName=天津医科大学肿瘤医院血液科, associationIntro=天津医科大学肿瘤医院血液科, copyright=0, guiderPublishedTime=Sun Jan 15 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">套细胞淋巴瘤(mantle cell lymphoma, MCL)是一种异质性很强的非霍奇金淋巴瘤,具有独特生物学、病理和临床特征,大多数患者诊断时即为晚期,预后较差。近年来随着大剂量化疗、自体造血干细胞移植及新药研究的进展,患者生存期得到明显延长。本文对《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》主要更新内容进行解读,旨在提高对该少见疾病的认识和诊疗水平。&nbsp;</span></p>, tagList=[TagDto(tagId=4848, tagName=套细胞淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=4848, articleKeyword=套细胞淋巴瘤, articleKeywordNum=6, guiderKeywordId=4848, guiderKeyword=套细胞淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=0, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2733, appHits=126, showAppHits=0, pcHits=397, showPcHits=2607, likes=0, shares=10, comments=3, approvalStatus=1, publishedTime=Wed Jan 25 09:54:00 CST 2023, publishedTimeString=2023-01-15, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=dajiong, createdTime=Tue Jan 17 09:55:14 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Wed Jan 03 14:54:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》解读.pdf)])
《套细胞淋巴瘤诊断与治疗中国指南(2022年版)》解读.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2118896, encodeId=091a21188966f, content=套细胞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=338a6306582, createdName=1028742_1728, createdTime=Sat Mar 11 10:21:44 CST 2023, time=2023-03-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2118895, encodeId=1c532118895f2, content=套细胞淋巴瘤发病率低,但发病时往往分期晚,难CR,所以规范治疗很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=338a6306582, createdName=1028742_1728, createdTime=Sat Mar 11 10:20:04 CST 2023, time=2023-03-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2117709, encodeId=6605211e70902, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a><a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44521, encryptionId=c4a844521e5, topicName=套细胞淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 10:48:37 CST 2023, time=2023-03-05, status=1, ipAttribution=上海)]
    2023-03-11 1028742_1728 来自福建省

    套细胞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2118896, encodeId=091a21188966f, content=套细胞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=338a6306582, createdName=1028742_1728, createdTime=Sat Mar 11 10:21:44 CST 2023, time=2023-03-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2118895, encodeId=1c532118895f2, content=套细胞淋巴瘤发病率低,但发病时往往分期晚,难CR,所以规范治疗很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=338a6306582, createdName=1028742_1728, createdTime=Sat Mar 11 10:20:04 CST 2023, time=2023-03-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2117709, encodeId=6605211e70902, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a><a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44521, encryptionId=c4a844521e5, topicName=套细胞淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 10:48:37 CST 2023, time=2023-03-05, status=1, ipAttribution=上海)]
    2023-03-11 1028742_1728 来自福建省

    套细胞淋巴瘤发病率低,但发病时往往分期晚,难CR,所以规范治疗很重要

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2118896, encodeId=091a21188966f, content=套细胞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=338a6306582, createdName=1028742_1728, createdTime=Sat Mar 11 10:21:44 CST 2023, time=2023-03-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2118895, encodeId=1c532118895f2, content=套细胞淋巴瘤发病率低,但发病时往往分期晚,难CR,所以规范治疗很重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=338a6306582, createdName=1028742_1728, createdTime=Sat Mar 11 10:20:04 CST 2023, time=2023-03-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2117709, encodeId=6605211e70902, content=<a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a><a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44521, encryptionId=c4a844521e5, topicName=套细胞淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 05 10:48:37 CST 2023, time=2023-03-05, status=1, ipAttribution=上海)]

拓展阅读

JCO:吡托布鲁替尼在先前共价BTK抑制剂治疗失败的套细胞淋巴瘤患者中显示出持久的疗效和良好的安全性

该研究结果显示吡托布鲁替尼是首个在先前共价BTK抑制剂治疗失败的复发/难治套细胞淋巴瘤患者中表现出持久的疗效的非共价BTK抑制剂,并且吡托布鲁替尼显示出良好的安全性。

【Blood Adv】CAR-T治疗套细胞淋巴瘤的神经毒性的临床特征

该研究或可改善MCL和其他血液系统恶性肿瘤患者中未来的CAR-T细胞疗法急性医疗。

Eur J Cancer:243例继发性CNS淋巴瘤的真实世界治疗模式和结局:一项前瞻性观察性研究

作者对SCNSL患者的真实世界治疗情况、危险因素和结局进行了全面的概述,尤其关注DLBCL患者,并报告了HDT-ASCT可改善对中枢神经系统导向治疗有效的患者的生存率。

【Lancet Haematol】辩论:对于R/R MCL,CAR-T还是异基因HSCT?

《The Lancet Haematology》近日发表一篇辩论(Debate)文章,就R/R MCL中CAR-T对比异基因HSCT进行了讨论。

【Blood】CAR-T联合伊布替尼治疗R/R MCL的2期TARMAC研究结果

因此澳大利亚学者开展一项研究者发起的II 期 TARMAC 研究,在20例 MCL 患者中评价了时间限制性伊布替尼联合CAR-T 治疗的疗效和安全性,研究的II期结果近日发表于《Blood》。

套细胞淋巴瘤的诊断和治疗:英国血液学会指南

旨在为医疗保健专业人员提供套细胞淋巴瘤患者诊断和治疗的明确指导。

2016 套细胞淋巴瘤诊断与治疗中国专家共识

中华医学会血液学分会白血病淋巴瘤学组 · 2016-09-30

2018 BSH指南:套细胞淋巴瘤的管理

英国血液病学学会(BSH,British Society for Haematology) · 2018-05-16

2023 BSH指南:套细胞淋巴瘤的诊断和管理

英国血液病学学会(BSH,British Society for Haematology) · 2023-10-25